Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.

摘要: We have tested several biomarkers [dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), thymidine phosphorylase (TP), thymidylate synthase (TS) and excision cross-complementing gene (ERCC1)] for their prognostic predictive value in relation to the outcome of chemotherapy tumour tissues 556 advanced colorectal cancer (ACC) patients who were randomised between sequential treatment combination CApecitabine, IRinotecan, Oxaliplatin (CAIRO) study. DPD expression showed a statistically significant with capecitabine plus irinotecan low versus high values resulting an improved median progression-free survival (PFS) overall (OS) 8.9 (95% confidence interval (CI) 8.3-9.9) 7.2 months CI 6.5-8.1, p=0.006), 21.5 17.9-26.5) 16.9 13.0-19.1, p=0.04), respectively. In patient population OPRT stromal cells was favourable parameter OS, 17.9-27.3) 17.2 15.1-18.6, p=0.036), A similar effect observed PFS. multivariate analysis that included known factors these results remained also unfavourable PFS OS. conclusion, this largest study on or without date we found expression. Our warrant further studies role treatments. The divergent ours previous underscore complexity currently prevent routine use markers daily clinical practice.